Is Electrocardiogram Helpful in Predicting a Rise in Troponin I as a Marker of Anthracycline Cardiotoxicity?
-
Published:2022-10-01
Issue:4
Volume:18
Page:299-305
-
ISSN:2587-0831
-
Container-title:European Journal of Breast Health
-
language:
-
Short-container-title:EJBH
Author:
Muneer KaderORCID,
Jose BennyORCID,
Dubey GajendraORCID,
T AjayakumarORCID,
CG SajeevORCID,
MN Krishnan
Publisher
Galenos Yayinevi
Subject
Ocean Engineering
Reference26 articles.
1. 1. Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol 2006; 33: 2-14. (PMID: 16473642) [Crossref]
2. 2. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-2879. (PMID: 12767102) [Crossref]
3. 3. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2002; 4: 235-242. (PMID: 12034146) [Crossref]
4. 4. Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004; 22: 1864-1871. (PMID: 15143078) [Crossref]
5. 5. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010; 10: 337. (PMID: 20587042) [Crossref]